title: Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
abstract: A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.
authors.affiliation: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shima
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kamezaki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Higashioka
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Takashima
authors.forename: Goichi
authors.initials: G
authors.lastname: Yoshimoto
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Muta
authors.forename: Katsuto
authors.initials: K
authors.lastname: Takenaka
authors.forename: Hiromi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001201:Ascites / Q000139:chemically induced*; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C549035:mogamulizumab